Alexion   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: New Haven CT United States (1992)
Status: Acquired by AstraZeneca (2020)

Organization Overview

First Clinical Trial
2002
NCT00048308
First Marketed Drug
2007
eculizumab (Soliris)
First NDA Approval
2007
eculizumab (Soliris)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Achillion, a wholly owned subsidiary of Alexion | Alexion | Alexion Antibody Technologies | ALEXION PHARM | Alexion Pharmaceuticals | Alexion Pharmaceuticals, Inc. | Alexion Pharma GmbH | Alexion Pharma Italy s.r.l.

Active Ingredients

Marketed Drugs (4)

Key: Alexion (3) Acquired (1)

asfotase alfa (strensiq) (2015 NDA)

eculizumab (Soliris) (2007 NDA)

ravulizumab-cwvz (ultomiris) (2018 NDA)

sebelipase alfa (kanuma) (2015 NDA)

Drugs in Phase 4 Trials (12)

Key: Alexion (2) Acquired (10)

abacavir (ziagen) (2 trials)

adenexanet alfa (9 trials)

asfotase alfa (strensiq) (13 trials)

atazanavir (reyataz) (1 trial)

darunavir (prezista) (1 trial)

eculizumab (Soliris) (53 trials)

enfuvirtide (fuzeon) (11 trials)

fosamprenavir (lexiva) (1 trial)

lamivudine (epivir) (5 trials)

lopinavir (Kaletra) (1 trial)

ravulizumab-cwvz (ultomiris) (23 trials)

ritonavir (Norvir) (2 trials)

Drugs in Phase 3 Trials (11)

Key: Alexion (2) Acquired (9)

ag10 (2 trials)

alxn1840 (12 trials)

betrixaban (bevyxxa) (11 trials)

cerdulatinib (3 trials)

danicopan (23 trials)

enoxaparin (lovenox) (2 trials)

Fosdenopterin (Nulibry) (4 trials)

penicillamine (cuprimine) (1 trial)

sebelipase alfa (kanuma) (8 trials)

triethylenetetramine (trientine) (1 trial)

zinc (1 trial)

Drugs in Phase 2 Trials (30)

Key: Alexion (7) Acquired (23)

ach-0137171 (1 trial)

alxn1007 (4 trials)

alxn1820 (2 trials)

alxn1830 (7 trials)

amiodarone (cordarone) (1 trial)

amprenavir (agenerase) (1 trial)

andexanet alfa (4 trials)

apixaban (eliquis) (2 trials)

bis-choline tetrathiomolybdate (2 trials)

b-l-fd4c (1 trial)

clopidogrel (plavix) (1 trial)

edoxaban (savaysa) (2 trials)

efavirenz (sustiva) (2 trials)

elinogrel (3 trials)

elvucitabine (7 trials)

emtricitabine (emtriva) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

odalasvir (3 trials)

ribavirin (virazole) (3 trials)

rivaroxaban (xarelto) (3 trials)

samalizumab (2 trials)

sargramostim (leukine) (1 trial)

sbc-103 (2 trials)

sodium chloride (2 trials)

sovaprevir (2 trials)

tenofovir (viread) (1 trial)

tifuvirtide (1 trial)

Vemircopan (13 trials)

warfarin (coumadin) (2 trials)

Drugs in Phase 1 Trials (24)

Key: Alexion (19) Acquired (5)

al-335 (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

alxn1102 (1 trial)

bupropion (wellbutrin) (2 trials)

calcium carbonate (1 trial)

celecoxib (celebrex) (1 trial)

cyclosporine (sandimmune) (2 trials)

digoxin (lanoxin) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fexofenadine (allegra) (1 trial)

fluconazole (diflucan) (1 trial)

Gefurulimab (2 trials)

hyaluronidase (human recombinant) (Hylenex) (2 trials)

itraconazole (sporanox) (1 trial)

magnesium hydroxide (1 trial)

midazolam (versed) (2 trials)

moxifloxacin (avelox) (3 trials)

mycophenolate (CellCept) (2 trials)

norethindrone (1 trial)

omeprazole (prilosec) (3 trials)

rifampin (1 trial)

simeprevir (olysio) (1 trial)

simethicone (IMODIUM) (1 trial)

tacrolimus (prograf) (2 trials)

Indications

Approved Indications


 

Atypical Hemolytic Uremic Syndrome

Cholesterol Ester Storage Disease

Hemoglobinuria, Paroxysmal

Hypophosphatasia

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Amyloidosis (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Anemia (Phase 2)

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 2)

Antiphospholipid Syndrome (Phase 2)

Asthma (Phase 2)

Atypical Hemolytic Uremic Syndrome (Phase 3)

Azotemia (Phase 3)

Cardiomyopathies (Phase 3)

Cholesterol Ester Storage Disease (Phase 2)

Coronary Artery Disease (Phase 3)

Death (Phase 2)

Delayed Graft Function (Phase 3)

Disease (Phase 3)

End Stage Liver Disease (Phase 1)

Failure to Thrive (Phase 3)

Geographic Atrophy (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Glomerulonephritis, Membranoproliferative (Phase 2)

Graft vs Host Disease (Phase 2)

Hemoglobinuria (Phase 4)

Hemoglobinuria, Paroxysmal (Phase 4)

Hemolysis (Phase 3)

Hemolytic-Uremic Syndrome (Phase 3)

Hepatolenticular Degeneration (Phase 3)

Hypophosphatasia (Phase 4)

Kidney Diseases (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Liver Diseases (Phase 1)

Lung Injury (Phase 3)

Lupus Nephritis (Phase 2)

Macular Degeneration (Phase 2)

Metal Metabolism, Inborn Errors (Phase 3)

Motor Neuron Disease (Phase 3)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis III (Phase 2)

Multiple Myeloma (Phase 2)

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Nephritis (Phase 2)

Neuromyelitis Optica (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 3)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Sclerosis (Phase 3)

Syndrome (Phase 3)

Thrombotic Microangiopathies (Phase 3)

Vascular Diseases (Phase 3)

Vasculitis (Phase 2)

Ventricular Dysfunction (Phase 4)

Ventricular Dysfunction, Left (Phase 4)

Wolman Disease (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 222
  • # of Trial APIs: 77